Namita Singh, MD

Pfizer
New York City, New York, United States

Disclosure(s): Pfizer: Employee, Stocks/Bonds (Public Company)

Presentation(s):

• 580 - Pharmacokinetics (PK) and Safety of Nirmatrelvir/Ritonavir (NMV/r) in Non-Hospitalized Symptomatic Pediatric Patients Ages 6 Years and Older with COVID-19 who are at Increased Risk of Progression to Severe Disease (EPIC-Peds)

  Saturday, October 19, 2024
  2:45 PM – 2:57 PM US PT